Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China The B cell-activating factor (BAFF) system, comprising two ligands and three receptors, plays a ...

The academics conducted in situ I–V monitoring during a 400 C annealing process of both conventional and LECO-treated TOPCon solar cells and applied independent bias cycles in a forward ...

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy ... and Robert Dawson, B.A. (of Cactus Communications), for assistance with earlier versions of the figures.

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) occurring in patients with advanced B-cell lymphoma (BCL).

B-cell lymphomas make up most (about 85%) of the non-Hodgkin lymphomas (NHL) in the United States. These types of lymphomas start in early forms of B lymphocytes (B cells). The most common types of ...

– Updated data from the pivotal Phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who ...

Bispecific T cell engagers (TcEs) are immunotherapeutic drugs that trigger the destruction of cancer cells by linking T cells to cancer cells through specific surface molecules (antigens). We designed ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Cells change their metabolic profiles in ...

CD20 expression levels correlate with outcomes in B-cell lymphoma patients treated with CD20xCD3 bispecific antibodies. Patients with reduced CD20 expression had significantly lower PFS and OS ...